Applied Genetic Technologies (AGTC) Misses Q4 EPS by 20c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AGTC Hot Sheet
Join SI Premium – FREE
Applied Genetic Technologies (NASDAQ: AGTC) reported Q4 EPS of ($0.37), $0.20 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $8.46 million.
“We have achieved significant progress across our broad and diverse portfolio of five ophthalmology development programs,” said Sue Washer, President and CEO of AGTC. “We expanded our clinical and medical leadership teams, maintained a robust balance sheet and ended our fiscal year with strong momentum having our highest annual enrollment in clinical trials to date.”
For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aptiv (APTV) Tops Q3 EPS by 9c; offers guidance
- Zebra Technologies (ZBRA) Tops Q3 EPS by 6c; offers guidance
- Dynatrace Inc. (DT) Tops Q2 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
